Expert Interview
Discussing Zymeworks’ Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs) with topline data from the HERIZON-BTC-01 Trial
Ticker(s): ZYMEInstitution: Duke University
- Instructor of Medical Oncology at Duke who treats gastrointestinal cancers and conducts research on tumor immunology and immunotherapy, particularly for melanoma and gastrointestinal malignancies.
- Laboratory and translational research is focused on tumor immune evasion and immunotherapy resistances, and the development of biomarkers with a specific interest in dendritic cell tolerance.
- Research and clinical goal of finding new immunotherapeutic options for patients with supportive biomarkers to identify patients.
Please describe your practice as a clinician,how many patients with Cholangiocarcinoma/biliary tract cancers do you see on a yearly basis? What percent are HER2-positive? Could you walk us through the standard of care, and take us through the most promising upcoming treatments, or interesting clinical trials in this space?
Considering there’s no approved HER2-targeted therapy for the treatment of BTC, what is your approach in treating those cases?
How much of an unmet need is there in HER2-positive cholangiocarcinoma?
Please discuss the new Phase 2b Topline Data In The Pivotal HERIZON-BTC-01 Trial Of Zanidatamab. How satisfactory are the results?
Zanidatamab monotherapy showed cORR of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC). How does it compare to presently available treatment choices?
How much use do you see for Zanidatamab in the future? How likely are you to prescribe it to your patients, based on the results to date?
- What is the role of Herceptin/trastuzumab in the current treatment of BTC?
- Does Zanidatamab appear to be differentiated from Herceptin based on this data?
- Is the concept behind Zanidatamab mechanism of action plausible that hitting multiple domains of HER2 will lead to cross linking and better activity than a traditional antibody with a single HER2 binding site? How does that work?
- If Herceptin is typically utilized in the first line for patients with HER2 expression, how useful will a 2nd line approval be? Will Zanidatamab find available patients for second line treatment?
- How would you rate your level of excitement about Zanidatamab in HER2 amplified or expressing BTC on a 1 to 10 scale, and why?
- What were your thoughts on the metastatic Gastroesophageal Adenocarcinoma (mGEA) data at ASCO-GI?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
